New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor

X. Feng, R. H. Pak, L. A. Kroger, J. K. Moran, D. G. DeNardo, C. F. Meares, G. L. DeNardo, S. J. DeNardo

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10- tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (Y-DOTA) and copper(II)- 1, 4, 8, 11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (Cu- TETA). Four hybridomas with high Y-DOTA binding activity and one hybridoma with Cu-TETA activity were selected. MAbs were purified from mouse ascites by Protein A affinity chromatography and characterized. Affinity constants were determined by equilibrium dialysis and the highest affinity Y-DOTA MAb (K(aff) = 1.9 x 108 M-1) was further characterized by competitive ELISA. Gd-DOTA competed as well as Y-DOTA, whereas In-DOTA required 740x higher concentrations for 50% inhibition of this Y-DOTA MAb binding to human serum albumin-Y-DOTA-coated microtiter plates. These anti-metal chelate MAbs have potential use as vehicles for the pretargeted delivery of radiometal chelates to tumors.

Original languageEnglish
Pages (from-to)125-132
Number of pages8
JournalHybridoma
Volume17
Issue number2
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint Dive into the research topics of 'New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor'. Together they form a unique fingerprint.

  • Cite this